Vergent Bioscience
MINNEAPOLIS, Minnesota, United States · Biotechnology, Health Care, Therapeutics
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors d
Key facts
- Headquarters
- MINNEAPOLIS, Minnesota, United States
- Employees
- Unknown
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- vergentbio.com
- Company page
Recent activity at Vergent Bioscience
- : Vergent Bioscience Appoints Adam Gridley as Chief Executive Officer
- : Vergent Bioscience
- : Vergent Bioscience
- : Vergent Bioscience announces FDA Fast Track designation for abenacianine injection to enhance tumor visualization during lung surgery.
- : Vergent Bioscience, Inc
- : Vergent Bioscience Secures $21.5 Million Series B Financing To Advance Clinical Development Of Tumor-Targeted Fluorescent Imaging Agent Vgt-309
- : Vergent Bioscience, Inc.
- : Vergent Bioscience, Inc.
- : Vergent Bioscience, Inc.
Vergent Bioscience funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Venture | $18.7M |
| Feb 2025 | Venture | $3.8M |
| Oct 2022 | Venture | $21.5M |
| Oct 2022 | Series B | $21.5M |
| Nov 2021 | Seed | $1.2M |
Leadership
- John Santini, President & CEO
- John Santini, Executive Officer, Director
- John Santini, Executive Officer, Director
- Jeffrey Julkowski, Director, Promoter
- Samuel Banks, Director
- Douglas Kohrs, Director
- Raymond Wong, Director
- Ryan Egeland, Director
- Raymond Wong, Director
- Douglas Kohrs, Director
- Samuel Banks, Director
- Jeffrey Julkowski, Director, Promoter
Verified email and direct lines for Vergent Bioscience’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Vergent Bioscience in the news
Companies similar to Vergent Bioscience
- Abcuro · Biotechnology, Health Care, Therapeutics
- ZoeNCure Therapeutics Pvt. Ltd · Biotechnology, Health Care, Therapeutics
- Amplifica Holdings Group · Biotechnology, Health Care, Therapeutics
- Morphic Holding · Biotechnology, Health Care, Therapeutics
- NYU Langone Health · Biotechnology, Health Care, Therapeutics
About Vergent Bioscience: questions and answers
What does Vergent Bioscience do?
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors d
Where is Vergent Bioscience headquartered?
Vergent Bioscience is headquartered in MINNEAPOLIS, Minnesota, United States.
Has Vergent Bioscience raised funding?
Yes. Fundz has recorded 5 funding events for Vergent Bioscience. The most recent, $18.7M, was in Oct 2025.
Who leads Vergent Bioscience?
John Santini is a President & CEO at Vergent Bioscience.
What is the latest news on Vergent Bioscience?
On Jun 09, 2026, Vergent Bioscience Appoints Adam Gridley as Chief Executive Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy